Riociguat, a soluble guanylate cyclase (sGC) stimulator, was approved for treatment of chronic thromboembolic pulmonary hypertension (CTEPH) in 2013 and pulmonary arterial hypertension (PAH) in 2015. The gene discussed is SGCB; the disease is chronic thromboembolic pulmonary hypertension.